Results 51 to 60 of about 26,436 (212)

HKDC1-mediated polyamine rewiring drives lenvatinib resistance and immune escape in hepatocellular carcinoma [PDF]

Clinical and Molecular Hepatology
Background/Aims Lenvatinib resistance and immune exclusion limit outcomes in hepatocellular carcinoma (HCC). We hypothesized that metabolic rewiring orchestrates resistance to lenvatinib and programmed cell death protein 1 (PD-1) blockade.
Shiping Chen, Biao Wang, Yang Zhang, Bing Quan, Yujie Shao, Guiqi Zhu, Jialiang Cai, Peiling Zhang, Lina Song, Jinglei Wan, Yi Yang, Junxian Du, Yufan Cai, Zhi Dai   +13 more
doaj   +1 more source

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

, 2017
Alessandro Leonetti, Francesco Leonardi, Melissa Bersanelli, Sebastiano Buti Medical Oncology Unit, University Hospital of Parma, Parma, Italy Introduction: Renal cell carcinoma (RCC) represents 2%–3% of all cancers in adults, and its ...
Leonetti A, Bersanelli M, Buti S., Leonetti A., Leonardi F., Bersanelli M., Leonardi F, Buti S   +7 more
core   +1 more source

USP4‐Dependent CHAF1B Stabilization Regulates Distinct SETDB1 Ubiquitin States Linked to AKT T308 Signaling and Lipogenic Remodeling in HCC

Advanced Science, EarlyView.
USP4 stabilizes CHAF1B by limiting K48‐linked ubiquitination. Stabilized CHAF1B supports UHRF1‐associated K63‐linked SETDB1 ubiquitination and cytoplasmic redistribution, whereas CHAF1B loss favors VHL‐dependent K11‐associated degradative ubiquitination and proteasomal loss of SETDB1.
Saiyan Bian, Yun Tong, Wenkai Ni, Zhangzhi Tang, Weiting Chen, Kexin Ma, Lihan Jiang, Jiayu Shao, Xuyang He, Wenjie Zheng   +9 more
wiley   +1 more source

Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation

Cancer Biology & Therapy
Lenvatinib, as a multi-kinase inhibitor, has been approved as a first-line drug for patients with advanced hepatocellular carcinoma (HCC). Gasdermin E (GSDME)-mediated pyroptosis, a form of programmed cell death, can be induced by chemotherapy drugs or ...
Yuan Yuan, Mu-Ru Wang, Yang Ding, Ya Lin, Ting-Ting Xu, Xing-Xing He, Pei-Yuan Li   +6 more
doaj   +1 more source

Clinical background of patients treated with lenvatinib.

, 2022
Clinical background of patients treated with lenvatinib.
Hiroshi Aikata (128663), Shigeki Yano (11965288), Eisuke Murakami (756173), Daiki Miki (128628), Yuwa Ando (11965300), Shinsuke Uchikawa (11032037), Kazuaki Chayama (128675), Shoichi Takahashi (128660), Wataru Okamoto (6496550), Masanari Kosaka (11965276), Serami Murakami (11965291), Akiko Nagao (2637289), Tomokazu Kawaoka (128666), Yumi Kosaka (11965303), Masami Yamauchi (8876237), Takuro Uchida (756174), Yusuke Johira (11965279), Kensuke Naruto (11965297), Takashi Nakahara (1677235), Ryoichi Miura (11965285), Hatsue Fujino (4348360), Michio Imamura (128656), Kenji Yamaoka (11965273), Yuki Shirane (11965282), Kenichiro Kodama (8876240), Kei Amioka (11965294)   +25 more
core   +1 more source

Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation

Advanced Science, EarlyView.
Incomplete microwave ablation induces animmunosuppressive microenvironment in tumor‐draining lymph nodes. An albumin‐based lipoprotein nanosystem enables coordinated delivery of immunomodulators to tumor‐draining lymph nodes and residual tumors, reverses post‐ablation immunosuppression, suppresses residual tumor growth, and promotes durable antitumor ...
Xuexia Shan, Yuting Shen, Xiaodong Hou, Fengshan Jin, Shaoyue Li, Weichen Xu, Weiwei Ren, Xiaowan Bo, Qiuyan Li, Shuo Liu, Weifan Hao, Chengzhong Peng, Huixiong Xu, Liping Sun, Wenwen Yue   +14 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver

Acta Pharmaceutica
Lenvatinib is an orally effective tyrosine kinase inhibitor used to treat several types of tumors, including progressive, radioiodine-refractory differentiated thyroid cancer and advanced renal cell carcinoma.
Indra Radek, Jelínková Sandra, Kollárová Katarína, Zahumenská Petra, Dvořák Josef, Dušková Šárka, Dračínská Helena   +6 more
doaj   +1 more source

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib

Case Reports in Oncology, 2018
Lenvatinib is an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, as well as platelet-derived growth factor receptor α, RET, and KIT.
Reiko Kimura-Tsuchiya, Eisaku Sasaki, Izumi Nakamura, Satoshi Suzuki, Satoshi Kawana, Chiyo Okouchi, Toshihiko Fukushima, Yuko Hashimoto, Shinichi Suzuki, Shigehira Saji   +9 more
doaj   +1 more source

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source